tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Sep;18(9):e70006.
doi: 10.1111/irv.70006. Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals
Yuan Gao[SUP] 1 [/SUP], Yixi Dong[SUP] 2 [/SUP], Qiushi Bu[SUP] 3 [/SUP], Zhijie Gong[SUP] 2 [/SUP], Wei Wang[SUP] 4 [/SUP], Zhongkai Zhou[SUP] 4 [/SUP], Yunyi Gao[SUP] 5 [/SUP], Liwei Liu[SUP] 1 [/SUP], Menghua Wu[SUP] 6 [/SUP], Jiaying Zhang[SUP] 7 [/SUP], Lianchun Liang[SUP] 7 [/SUP], Hongjun Li[SUP] 4 [/SUP], Mengxi Jiang[SUP] 8 [/SUP], Zujin Luo[SUP] 9 [/SUP], Yingmin Ma[SUP] 10 [/SUP], Xinyu Zhang[SUP] 2 3 [/SUP], Zhongjie Hu[SUP] 11 [/SUP]
Affiliations
Introduction: There is still a lack of clinical evidence comprehensively evaluating the effectiveness of antiviral treatments for COVID-19 hospitalized patients.
Methods: A retrospective cohort study was conducted at Beijing You'An Hospital, focusing on patients treated with nirmatrelvir/ritonavir or azvudine. The study employed a tripartite analysis-viral dynamics, survival curve analysis, and AI-based radiological analysis of pulmonary CT images-aiming to assess the severity of pneumonia.
Results: Of 370 patients treated with either nirmatrelvir/ritonavir or azvudine as monotherapy, those in the nirmatrelvir/ritonavir group experienced faster viral clearance than those treated with azvudine (5.4 days vs. 8.4 days, p < 0.001). No significant differences were observed in the survival curves between the two drug groups. AI-based radiological analysis revealed that patients in the nirmatrelvir group had more severe pneumonia conditions (infection ratio is 11.1 vs. 5.35, p = 0.007). Patients with an infection ratio higher than 9.2 had nearly three times the mortality rate compared to those with an infection ratio lower than 9.2.
Conclusions: Our study suggests that in real-world studies regarding hospitalized patients with COVID-19 pneumonia, the antiviral effect of nirmatrelvir/ritonavir is significantly superior to azvudine, but the choice of antiviral agents is not necessarily linked to clinical outcomes; the severity of pneumonia at admission is the most important factor to determine prognosis. Additionally, our findings indicate that pulmonary AI imaging analysis can be a powerful tool for predicting patient prognosis and guiding clinical decision-making.
Keywords: COVID‐19; antiviral; artificial intelligence image; viral dynamics.
. 2024 Sep;18(9):e70006.
doi: 10.1111/irv.70006. Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals
Yuan Gao[SUP] 1 [/SUP], Yixi Dong[SUP] 2 [/SUP], Qiushi Bu[SUP] 3 [/SUP], Zhijie Gong[SUP] 2 [/SUP], Wei Wang[SUP] 4 [/SUP], Zhongkai Zhou[SUP] 4 [/SUP], Yunyi Gao[SUP] 5 [/SUP], Liwei Liu[SUP] 1 [/SUP], Menghua Wu[SUP] 6 [/SUP], Jiaying Zhang[SUP] 7 [/SUP], Lianchun Liang[SUP] 7 [/SUP], Hongjun Li[SUP] 4 [/SUP], Mengxi Jiang[SUP] 8 [/SUP], Zujin Luo[SUP] 9 [/SUP], Yingmin Ma[SUP] 10 [/SUP], Xinyu Zhang[SUP] 2 3 [/SUP], Zhongjie Hu[SUP] 11 [/SUP]
Affiliations
- PMID: 39284764
- DOI: 10.1111/irv.70006
Introduction: There is still a lack of clinical evidence comprehensively evaluating the effectiveness of antiviral treatments for COVID-19 hospitalized patients.
Methods: A retrospective cohort study was conducted at Beijing You'An Hospital, focusing on patients treated with nirmatrelvir/ritonavir or azvudine. The study employed a tripartite analysis-viral dynamics, survival curve analysis, and AI-based radiological analysis of pulmonary CT images-aiming to assess the severity of pneumonia.
Results: Of 370 patients treated with either nirmatrelvir/ritonavir or azvudine as monotherapy, those in the nirmatrelvir/ritonavir group experienced faster viral clearance than those treated with azvudine (5.4 days vs. 8.4 days, p < 0.001). No significant differences were observed in the survival curves between the two drug groups. AI-based radiological analysis revealed that patients in the nirmatrelvir group had more severe pneumonia conditions (infection ratio is 11.1 vs. 5.35, p = 0.007). Patients with an infection ratio higher than 9.2 had nearly three times the mortality rate compared to those with an infection ratio lower than 9.2.
Conclusions: Our study suggests that in real-world studies regarding hospitalized patients with COVID-19 pneumonia, the antiviral effect of nirmatrelvir/ritonavir is significantly superior to azvudine, but the choice of antiviral agents is not necessarily linked to clinical outcomes; the severity of pneumonia at admission is the most important factor to determine prognosis. Additionally, our findings indicate that pulmonary AI imaging analysis can be a powerful tool for predicting patient prognosis and guiding clinical decision-making.
Keywords: COVID‐19; antiviral; artificial intelligence image; viral dynamics.